Paving the way to better care

A public-private international research collaboration aiming to personalise prevention and treatment of cardiovascular disease.

What moves us

The challenge of cardiovascular disease

Cardiovascular disease (CVD) is a highly prevalent disease that poses challenges to healthcare systems worldwide. In Europe alone, it affects over 85 million people – a number that is rising due to an aging population and unhealthy lifestyles. 

Despite medical advancements, treating CVD effectively remains challenging due to the complex interplay of risk factors and co-existing conditions in patients, such as diabetes and hypertension.  

While a “one size fits all” approach persists, the diverse nature of CVD calls for personalized treatment strategies that improve care for patients. That’s the ultimate goal of iCARE4CVD.

iCARE4CVD's vision is to work towards a future where CVD is better understood, more effectively treated, and less devastating for individuals and communities.

Number of people affected by CVD

> 500 million worldwide

Number of people that die from CVD

~ 17 million worldwide

iCARE4CVD approach

From one-size-fits-all to personalised care

By creating one database gathering data from more than 1 million patients and using artificial intelligence, iCARE4CVD will look for new strategies to shift from a one-size-fits-all approach to personalised care.

The project will focus on improving four key areas of current CVD healthcare by:

34 leading partners

from civil society, academia, and industry

22 million EUR

in funding

4.5 years

of project duration

Play Video

The project will achieve this by:

Collecting large amounts of patient cohorts...

covering patients of all CVD stages - from early risk to established heart failure

Generating a federated database...

to ensure private and confidential remote access to data on an individual level

Determining the value of biomarkers from different sources...

such as blood, imaging, digital wearables, to support early detection, monitoring, and treatment guidance for the entire spectrum of patients

Conducting in-depth qualitative research with patients and other stakeholders...

to build a motivational framework for self-care by patients and ensure their needs are incorporated into the outputs of the project

Developing artificial intelligence (AI)-based models to support diagnosis and predict risk and treatment responses...

to map the complete patient journey and response to interventions in CVD

Validating AI-based models prospectively towards precision medicine...

enabling the development of personalized care pathways

iCARE4CVD partners

iCARE4CVD brings together 33 leading international partners from civil society, academia and industry, and is lead by Maastricht University and global
healthcare company Novo Nordisk.

WIG2
UMCG
AZG
IRFMN
FCI
UKA
Novo Nordisk
Deutsches Herzzentrum der Charité
Orbital
IMEC
Charité
Catalyze
University of Glasgow
Mondor Institute for Biomedical Research
Huawei
Medizinische Universität Wien
University Medical Center Groningen
Uniklinik RWTH Aachen
Amgen
TNO
Astra Zeneca
Scientific Institute for Health Economics and Health Systems Research
Decentriq
German Foundation for the Chronically Ill
Erasmus MC
Philips
Human Technopole
Mario Negri Pharmacological Research Institute
IMRB
JDRF
Bayer
Maastricht University
Evotec
French-Speaking Society of the Type 1 Diabetes Cohort
Leiden University Medical Center
Queen’s University Belfast
Roche
Swiss Institute Of Bioinformatics
Thomas More
University College Dublin
Lilly
Have any questions?

Send us a message.

Project coordinator:

  • Hans-Peter Brunner La-Rocca (Maastricht University)

 

Project lead:

  • Nicholas Ciccone (Novo Nordisk)

 

Project managers:

  • Misha Schepers (Maastricht University
  • Mafalda Ferreira (Catalyze)

Stay In the loop:
Subscribe to our newsletter

Subscribe to our newsletter to stay up to date with all the most recent information about iCARE4CVD.